Changes in zolpidem exposure cases in the national poison data system after FDA drug safety communications

被引：0
|
作者：
Zhou, Esther [1 ]
Feng, Zhou [1 ]
Pinnow, Ellen [1 ]
Lee, Joann [1 ]
Vega, Amarilys [1 ]
DalPan, Gerald [1 ]
机构：
[1] US FDA, Silver Spring, MD USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
3969
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [1] Trend changes of national zolpidem users and exposure cases after FDA drug safety communications
    Zhou, Esther H.
    Feng, Zhou
    Pinnow, Ellen
    Lee, Joann
    Bak, Daniel
    Ready, Travis
    Dal Pan, Gerald J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (11) : 1551 - 1559
  • [2] Changes in emergency department visits for zolpidem-attributed adverse drug reactions after FDA Drug Safety Communications
    Geller, Andrew I.
    Zhou, Esther H.
    Budnitz, Daniel S.
    Lovegrove, Maribeth C.
    Dal Pan, Gerald J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (03) : 352 - 356
  • [3] Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications
    Kesselheim, Aaron S.
    Donneyong, Macarius
    Dal Pan, Gerald J.
    Zhou, Esther H.
    Avorn, Jerry
    Schneeweiss, Sebastian
    Seeger, John D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (06) : 712 - 721
  • [4] Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem
    Aaron S. Kesselheim
    Michael S. Sinha
    Eric G. Campbell
    Sebastian Schneeweiss
    Paula Rausch
    Brian M. Lappin
    Esther H. Zhou
    Jerry Avorn
    Gerald J. Dal Pan
    Drug Safety, 2019, 42 : 1287 - 1295
  • [5] Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem
    Kesselheim, Aaron S.
    Sinha, Michael S.
    Campbell, Eric G.
    Schneeweiss, Sebastian
    Rausch, Paula
    Lappin, Brian M.
    Zhou, Esther H.
    Avorn, Jerry
    Dal Pan, Gerald J.
    DRUG SAFETY, 2019, 42 (11) : 1287 - 1295
  • [6] Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis
    Woloshin, Steve
    Schwartz, Lisa M.
    Dejene, Sara
    Rausch, Paula
    Dal Pan, Gerald J.
    Zhou, Esther H.
    Kesselheim, Aaron S.
    JOURNAL OF HEALTH COMMUNICATION, 2017, 22 (05) : 365 - 372
  • [7] Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey
    Kesselheim, Aaron S.
    Sinha, Michael S.
    Rausch, Paula
    Lu, Zhigang
    Tessema, Frazer A.
    Lappin, Brian M.
    Zhou, Esther H.
    Dal Pan, Gerald J.
    Zwanziger, Lee
    Ramanadham, Amy
    Loughlin, Anita
    Enger, Cheryl
    Avorn, Jerry
    Campbell, Eric G.
    JOURNAL OF LAW MEDICINE & ETHICS, 2019, 47 (03): : 430 - 441
  • [8] Trends in US emergency department visits for zolpidem-related adverse events before and after FDA drug safety communications, 2010-2016
    Geller, Andrew I.
    Budnitz, Daniel S.
    Zhou, Esther H.
    Lovegrove, Maribeth C.
    Dal Pan, Gerald J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 206 - 207
  • [9] Trends in US Emergency Department visits for zolpidem-related adverse events before and after FDA Drug Safety Communications, 2010-2016
    Andrew
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 286 - 286
  • [10] Tracking Melamine Exposure Calls Via the National Poison Data System
    Skinner, C. G.
    Wolkin, A.
    Bronstein, A. C.
    Cooper, C. G.
    Thomas, R.
    Thomas, J. D.
    Schier, J. G.
    CLINICAL TOXICOLOGY, 2009, 47 (07) : 758 - 758
12345